scispace - formally typeset
F

Farzin Haque

Researcher at University of Kentucky

Publications -  47
Citations -  4170

Farzin Haque is an academic researcher from University of Kentucky. The author has contributed to research in topics: RNA & Ribozyme. The author has an hindex of 32, co-authored 47 publications receiving 3582 citations. Previous affiliations of Farzin Haque include Markey Cancer Center & Purdue University.

Papers
More filters
Journal ArticleDOI

Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics.

TL;DR: The three-way junction domain of the phi29 bacteriophage can be assembled from three pieces of RNA oligomers to form stable multifunctional nanoparticles that are useful for the treatment of different diseases.
Journal ArticleDOI

Solid-state and biological nanopore for real-time sensing of single chemical and sequencing of DNA

TL;DR: This review covers current nanopore detection platforms including both biological pores and solid state counterparts and focuses on the three best characterized systems including α-hemolysin and MspA, both containing a smaller channel for the detection of single-strand DNA, as well as bacteriophage phi29 DNA packaging motor connector that contains a larger channel forThe passing of double stranded DNA.
Journal ArticleDOI

Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression

TL;DR: The orientation of arrow-shaped RNA was altered to control ligand display on extracellular vesicle membranes for specific cell targeting, or to regulate intracellular trafficking of small interfering RNA (siRNA) or microRNA (miRNA) in cancer treatment.
Journal ArticleDOI

Advancement of the Emerging Field of RNA Nanotechnology.

TL;DR: This review aims to outline the current state of the art of RNA nanoparticles as programmable smart complexes and offers perspectives on the promising avenues of research in this fast-growing field.
Journal ArticleDOI

Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.

TL;DR: The application of RNA nanotechnology for specific and efficient delivery of anti-miR-21 to block the growth of TNBC in orthotopic mouse models is reported here and demonstrates the clinical potentials ofRNA nanotechnology based platform to deliver miRNA based therapeutics for cancer treatment.